ArticleJCO precision oncology2020
Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials.
Article in JCO precision oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- TrialTriage, a Semiautonomous Prescreening Workflow for Resolving Ambiguity in Phase I Oncology Trial Eligibility: Development and Proof-of-Concept Study Using Synthetic Cases.JMIR formative research · 2026Article
- Real-World Data From a Molecular Tumor Board-Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?Cancer medicine · 2025Article
- Metabolic reprogramming and prognostic insights in molecular landscapes driven by glycolysis in ovarian cancer.Scientific reports · 2025Article
- Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data.EClinicalMedicine · 2024Article
- Incorporating Novel Technologies in Precision Oncology for Colorectal Cancer: Advancing Personalized Medicine.Cancers · 2024Review
- Lessons learned: the first consecutive 1000 patients of the CCCMunichJournal of cancer research and clinical oncology · 2023Review
- Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichTargeted oncology · 2023Article
- An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry.JCO precision oncology · 2022Review
- Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe.Journal of personalized medicine · 2022Article
- The Porto European Cancer Research Summit 2021.Molecular oncology · 2021Article
- Precision oncology in metastatic colorectal cancer - from biology to medicine.Nature reviews. Clinical oncology · 2021Review
- The Community Oncology and Academic Medical Center Alliance in the Age of Precision Medicine: Cancer Genetics and Genomics Considerations.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most academic precision oncology programs have been designed to facilitate enrollment of patients in early clinical trials with matched targeted agents. Over the last decade, major changes were seen both in the targetable molecular alteration landscape and in drug development trends. In this article, we describe how the Vall d'Hebron Institute of Oncology molecular prescreening program adapted to a dynamic model of biomarker-drug codevelopment. We started with a tumor-agnostic hotspot mutation panel plus in situ hybridization and immunohistochemistry of selected markers and subsequently transitioned to tumor-specific amplicon-based next-generation sequencing (NGS) tests together with custom copy number, fusion, and outlier gene expression panels. All assays are optimized for archived formalin-fixed paraffin-embedded tumor tissues without matched germline sequencing. In parallel, biomarker-matched trials evolved from a scenario of few targets and large populations (such as PI3K inhibitors in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.